MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
16.00
+0.25
+1.59%
Opening 09:46 02/11 EST
OPEN
15.66
PREV CLOSE
15.75
HIGH
16.00
LOW
15.52
VOLUME
10.96K
TURNOVER
--
52 WEEK HIGH
16.00
52 WEEK LOW
3.350
MARKET CAP
584.47M
P/E (TTM)
-7.0931
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Boston Scientific (BSX)
TipRanks · 1d ago
Weekly Report: what happened at CTNM last week (0202-0206)?
Weekly Report · 2d ago
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Sale of Common Shares
Reuters · 5d ago
Weekly Report: what happened at CTNM last week (0126-0130)?
Weekly Report · 02/02 10:34
Contineum Therapeutics CMO Tim Watkins Reports Sale of Common Shares
Reuters · 01/30 21:52
BRIEF-Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule
Reuters · 01/28 21:28
Contineum Therapeutics Grants Stock Options to New Employee Under Inducement Plan
Reuters · 01/28 21:05
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 01/28 15:05
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.